Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-88998377 · 1 trial · 3 indications
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non-investigational) product. It does not necessarily have a causal relationship with the investigational product.
Number of participant with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematological or hematological toxicity.
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Escalation | EXPERIMENTAL | Participants will receive JNJ-88998377 at a selected starting dose. Subsequent dose levels and schedules will be selected based on the review of all available data to establish recommended Phase 2 dose (RP2D). |
| Part B: Dose Expansion | EXPERIMENTAL | Participants will receive JNJ-88998377 at RP2D determined in Part A. Additional expansion cohort(s) may be added with a lower RP2D(s), or different dose schedule(s) based on all available data. |
| Name | Type | Description |
|---|---|---|
| JNJ-88998377 | DRUG | JNJ-88998377 will be administered. |
Inclusion Criteria: * Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease * Participants have measurable disease or meet all requirements for adequate...
JNJ-88998377 is an investigational small molecule being studied for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). It is currently in Phase 1 clinical development for this indication, which includes conditions such as relapsed B-cell NHL and refractory B-cell NHL.
The molecular target of JNJ-88998377 has not been disclosed. It is a small molecule being developed by Johnson & Johnson for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma, but its specific mechanism of action has not been publicly detailed.
JNJ-88998377 is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
JNJ-88998377 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in an active but not recruiting clinical trial for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
JNJ-88998377 is being evaluated in a Phase 1 clinical trial with the identifier NCT06470438. This study is titled 'A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma' and is currently active but not recruiting. The trial has an enrollment of 58 participants and is being conducted in multiple countries including China, Italy, Japan, Poland, South Korea, Taiwan, and Turkey.
JNJ-88998377 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. The drug has not yet completed clinical trials or received regulatory approval from the FDA or any other regulatory authority.